Ocumetics Strengthens Balance Sheet with $1.4 Million Debt Conversion Ahead of Key Clinical Milestones
June 2nd, 2026 1:21 PM
By: Newsworthy Staff
Ocumetics Technology Corp. converted $1.4 million of debenture principal into common shares, reducing debt by 35% and improving financial flexibility as it advances toward regulatory milestones for its vision restoration technology.
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that debentureholders have converted $1.4 million of principal into common shares at $0.32 per share, issuing 4,375,000 shares. This conversion reduces outstanding debenture principal by 35%, from $4 million to $2.6 million, significantly strengthening the company's balance sheet as it approaches critical patient study milestones.
The debt-to-equity conversion is expected to lower ongoing interest costs and improve financial flexibility, aligning investor interests with the company's clinical development objectives. President and CEO Dean Burns stated, "These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision."
Ocumetics is advancing toward key regulatory milestones, including preparation for an Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration. The company is conducting a first-in-human early feasibility study for its dynamic intraocular lens, designed to restore natural accommodation by using the eye's muscles to shift focus from distance to near, potentially eliminating the need for corrective lenses.
With a stronger balance sheet, Ocumetics aims to reduce financial risk and focus resources on clinical development. The conversion also signals stakeholder confidence in the technology's potential to transform ophthalmology. For more details, view the original release on NewMediaWire.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
